Investigating RNA sequences and their modifications to improve understanding of diseases.
Official title: Exhaustive de novo sequencing of every RNA in a sample by a layer-by-layer mass spectrometry ladder intensity approach.
Funded at Directseq Biosciences, INC. · NIH-11003488 · Data updated 2026-11-12
This study is looking at RNA, which plays a big role in diseases like breast cancer, using a new method to get a clearer picture of its details, so we can better understand how these diseases work and find new ways to treat them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Directseq Biosciences, INC. NIH-funded |
| Lab location | 1 site (Woodcliff Lake, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $215,088 |
| NIH project number | 1R41HG014125-01 |
| Project ID | NIH-11003488 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with breast cancer, skin cancer, lung cancer, or other diseases linked to RNA modification defects.
✕Less likely to help
Patients without any RNA-related diseases or those not affected by the specific conditions being studied may not benefit from this research.
What this research studies
This research focuses on the comprehensive analysis of RNA sequences and their modifications, which are crucial for understanding various diseases, including breast cancer. The approach utilizes a novel layer-by-layer mass spectrometry technique to capture every RNA molecule in a sample, addressing the limitations of current sequencing technologies that often miss critical information. By directly analyzing RNA without converting it to cDNA, the study aims to provide a more accurate representation of RNA content and modifications, which could lead to better insights into disease mechanisms and potential treatments.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic and therapeutic strategies for patients with RNA-related diseases.
How similar studies have gone: While RNA sequencing has been explored in various contexts, this specific approach using layer-by-layer mass spectrometry is innovative and has not been widely tested in previous studies.
Where this research is happening
-
Directseq Biosciences, INC.
Woodcliff Lake, United States Active
Researchers
- Principal investigator: Zhang, Shenglong — Directseq Biosciences, INC.
- Study coordinator: Zhang, Shenglong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.